It hasn't been a great morning session for Summit Therapeutics investors, who have watched their shares sink by -2.3% to a price of $11.6. Some of you might be wondering if it's time to buy the dip. If you are considering this, make sure to check the company's fundamentals first to determine if the shares are fairly valued at today's prices.
Summit Therapeutics's P/B and P/E Ratios Are Higher Than Average:
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 27.61 and an average price to book (P/B) ratio of 3.69. In contrast, Summit Therapeutics has a trailing 12 month P/E ratio of -105.5 and a P/B ratio of 43.12.
Summit Therapeutics has moved 504.2% over the last year compared to 26.2% for the S&P 500 — a difference of 477.9%. Summit Therapeutics has a 52 week high of $11.9 and a 52 week low of $1.52.
No Revenues With Decreasing Reinvestment in the Business:
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $37,958 | $583 | $860 | $1,809 | $705 | n/a |
| Net Income (k) | -$8,128 | -$22,032 | -$52,697 | -$88,602 | -$78,782 | -$614,928 |
| Net Interest Expense (k) | $1,544 | $620 | $255 | $242 | -$6,693 | -$5,278 |
| Depreciation & Amort. (k) | $198 | $409 | $302 | $330 | $349 | $198 |
| Diluted Shares (k) | 13,087 | 32,829 | 69,524 | 13,171 | 19,334 | 619,646 |
| Earnings Per Share | -$0.1 | -$0.13 | -$0.76 | -$0.67 | -$0.41 | -$0.99 |
| Avg. Price | $7.27 | $1.57 | $3.23 | $6.24 | $1.92 | $11.6 |
| P/E Ratio | -72.7 | -12.08 | -4.25 | -9.31 | -4.68 | -11.72 |
| Free Cash Flow (k) | -$22,169 | -$35,263 | -$48,532 | -$72,893 | -$42,206 | -$76,888 |
| CAPEX (k) | $668 | $157 | $421 | $306 | $624 | $128 |
| Current Ratio | 1.56 | 5.78 | 4.41 | 3.8 | 16.93 | 9.3 |
